ADMA Biologics Inc (NASDAQ:ADMA) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $11.58.
ADMA has been the topic of a number of recent research reports. Oppenheimer set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research report on Wednesday, September 5th. HC Wainwright initiated coverage on ADMA Biologics in a research report on Tuesday, October 30th. They set a “buy” rating and a $17.00 price objective on the stock. Maxim Group upped their price objective on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 26th. BidaskClub upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Raymond James restated a “buy” rating and set a $10.00 price objective (down from $11.00) on shares of ADMA Biologics in a research report on Friday, October 12th.
A number of hedge funds have recently modified their holdings of ADMA. BlackRock Inc. raised its position in ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 15,115 shares during the period. JPMorgan Chase & Co. purchased a new stake in ADMA Biologics during the first quarter valued at approximately $182,000. Millennium Management LLC raised its position in ADMA Biologics by 305.2% during the first quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock valued at $1,259,000 after purchasing an additional 206,088 shares during the period. Bank of New York Mellon Corp raised its position in ADMA Biologics by 188.0% during the second quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 35,791 shares during the period. Finally, Schwab Charles Investment Management Inc. purchased a new stake in ADMA Biologics during the second quarter valued at approximately $160,000. Institutional investors and hedge funds own 55.07% of the company’s stock.
Shares of ADMA Biologics stock opened at $5.26 on Wednesday. ADMA Biologics has a 12 month low of $2.10 and a 12 month high of $6.96. The company has a market cap of $266.97 million, a P/E ratio of -2.75 and a beta of 2.28. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. The firm had revenue of $4.23 million for the quarter, compared to the consensus estimate of $5.39 million. Research analysts predict that ADMA Biologics will post -1.36 earnings per share for the current year.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Story: Stock Symbols and CUSIP Explained
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.